Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting

CompletedOBSERVATIONAL
Enrollment

270

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

May 31, 2014

Conditions
Type 2 Diabetes Mellitus
Interventions
DEVICE

V-Go™

Use of Insulin Delivery Device, V-Go, and the effect on A1C for T2DM patients in five categories of baseline oral antidiabetes drug (OAD) use with or without insulin.

Trial Locations (25)

10301

University Physicians Group, Staten Island

11042

North Shore Diabetes & Endocrine Assoc., New Hyde Park

11787

Endocrine Associates of Long Island, PC, Smithtown

Middle Country Endocrinology, P.C., Smithtown

19047

Alan B. Schorr, DO FACE, Langhorne

21204

MODEL Clinical Research, Baltimore

27103

PMG Research of Winston-Salem, Winston-Salem

27834

Physicians East, PA, Greenville

28557

Diabetes & Endocrinology Consultants, Morehead City

Down East Medical Associates, Morehead City

30076

Endocrine Research Solutions, Inc., Roswell

30309

Atlanta Diabetes Associates, Atlanta

30338

Albert Johary M.D., P.C., Dunwoody

33952

MEDSOL Clinical Research Center, Port Charlotte

37403

University Diabetes & Endocrine Consultants, Chattanooga

37620

PMG Research of Bristol, Bristol

37919

PMG Research of Knoxville, Knoxville

48302

Grunberger Diabetes Institute, Bloomfield Hills

67211

MidAmerica Diabetes Associates, Wichita

87505

Regional Endocrinology Associates, PC, Santa Fe

91911

San Diego Coastal Endocrinology Group, Chula Vista

94110

Nancy J. Bohannon Med. Corp, San Francisco

06810

Western Connecticut Health Network, Inc., Danbury

07834

North Jersey Endocrine Consultants, LLCAND, Denville

07054

Parsippany Endocrine, LLC, Parsippany

Sponsors
All Listed Sponsors
collaborator

Integrated Medical Development

INDUSTRY

lead

Valeritas, Inc.

INDUSTRY